2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception

Keyphrases

• Alzheimer's Disease 100%
• Alzheimer's Disease Neuroimaging Initiative 100%
• Alzheime's Disease 87%
• Cerebrospinal Fluid Biomarkers 75%
• Clinical Test 37%
• Mild Cognitive Impairment 25%
• Rate of Change 25%
• Early Detection 25%
• Cardiac Magnetic Resonance Imaging (cMRI) 25%
• Amyloid Positron Emission Tomography 25%
• Quantitative Imaging 12%
• Neurodegeneration 12%
• Brain Atrophy 12%
• Europe 12%
• Control Subjects 12%
• Genome-wide Association Study 12%
• Disease Severity 12%
• China 12%
• Japan 12%
• Clinical Data 12%
• Change Patterns 12%
• 18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET) 12%
• Alzheimer's Disease Risk 12%
• Alzheimer's Disease Pathology 12%
• Competing Hypotheses 12%
• Multimodality 12%
• Early Alzheimer's Disease 12%
• Disease-modifying Therapy 12%
• Normal Aging 12%
• Blood Biomarkers 12%
• Preclinical Imaging 12%
• Biochemical Biomarkers 12%
• Longitudinal Data 12%
• Pathobiology 12%
• Imaging Biomarkers 12%
• Low-cost Alternative 12%
• Clinical Dementia Rating 12%
• Australia 12%
• Biomarker Testing 12%
• Risk Loci 12%
• Imaging Genetics 12%
• Quantitative Biomarkers 12%
• Alzheimer 12%
• Tau Positron Emission Tomography 12%
• Diagnostic Methods 12%
• Mildly Symptomatic 12%
• Italy 12%
• Etiopathogenesis 12%
• Cognitively Normal Elderly 12%
• Process Data 12%
• Elderly Controls 12%
• Disease Trajectory 12%
• Clinical Decline 12%
• Alzheimer's Disease Diagnosis 12%
• Longitudinal Magnetic Resonance Imaging 12%
• Clinical Biomarkers 12%
• Biomarker Data 12%
• ARGENTINA 12%
• Standardized Method 12%
• Taiwan 12%
• Embargo 12%
• Amnestic Mild Cognitive Impairment (aMCI) 12%
• Brain Hypometabolism 12%
• Multimodal Method 12%
• Alzheimer Patients 12%
• Alternative Assessment 12%
• Amyloid Cascade 12%
• PICALM 12%
• Reduced Sample Size 12%
• Early Tracking 12%
• Positron Emission Tomography/computed Tomography (PET/CT) 12%
• Preclinical Stage 12%
• Biomarker Assessment 12%
• Genetic Biomarkers 12%
• Cognitive Impairment Diseases 12%
• Clinical Trial Efficiency 12%
• Optimum Features 12%

Biochemistry, Genetics and Molecular Biology

• Positron Emission Tomography 100%
• Amyloid Protein 100%
• Magnetic Resonance Imaging 75%
• Tau 50%
• Sample Size 50%
• Clinical Trial 25%
• Genome-Wide Association Study 25%
• Imaging Genetics 25%
• PICALM 25%

Neuroscience

• Alzheimer's Disease 100%
• Biological Marker 50%
• Positron Emission Tomography 18%
• Amyloid Protein 18%
• Mild Cognitive Impairment 13%
• Magnetic Resonance Imaging 13%
• Neurodegeneration 4%
• Genome-Wide Association Study 4%
• Fluorine-18 4%
• Clinical Dementia Rating 4%
• Quantitative Imaging 4%
• Genetics 4%